Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Methods in molecular biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-1-4939-0956-8_13PMID 25150875
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Retraction: Integrative genomics identifies APOE ε4 effectors in Alzheimer’s disease

  2015cited by this paper
• Reduced 25‐hydroxyvitamin D and risk of Alzheimer's disease and vascular dementia

  2014cited by this paper
• Intra-Hippocampal Transplantation of Neural Precursor Cells with Transgenic Over-Expression of IL-1 Receptor Antagonist Rescues Memory and Neurogenesis Impairments in an Alzheimer’s Disease Model

  2014cited by this paper
• Rare autosomal copy number variations in early-onset familial Alzheimer’s disease

  2014cited by this paper
• Therapeutic and preventive effects of methylene blue on Alzheimer's disease pathology in a transgenic mouse model.

  2014cited by this paper
• Nardilysin prevents amyloid plaque formation by enhancing α-secretase activity in an Alzheimer's disease mouse model.

  2014cited by this paper
• The future of blood‐based biomarkers for Alzheimer's disease

  2014cited by this paper
• Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele.

  2014cited by this paper
• Targeting CNS transporters for treatment of neurodegenerative diseases.

  2014cited by this paper
• Global brain hypoperfusion and oxygenation in amnestic mild cognitive impairment

  2014cited by this paper
• Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer’s disease

  2014cited by this paper
• Dual-energy precursor and nuclear erythroid-related factor 2 activator treatment additively improve redox glutathione levels and neuron survival in aging and Alzheimer mouse neurons upstream of reactive oxygen species.

  2014cited by this paper
• St. John's Wort Reduces Beta‐Amyloid Accumulation in a Double Transgenic Alzheimer's Disease Mouse Model—Role of P‐Glycoprotein

  2014cited by this paper
• Involvement of α7 nAChR Signaling Cascade in Epigallocatechin Gallate Suppression of β-Amyloid-Induced Apoptotic Cortical Neuronal Insults

  2014cited by this paper
• Cortical sources of resting state electroencephalographic alpha rhythms deteriorate across time in subjects with amnesic mild cognitive impairment.

  2014cited by this paper
• Vitamin D supplementation restores suppressed synaptic plasticity in Alzheimer's disease

  2014cited by this paper
• Epitope‐based DNA vaccine for Alzheimer's disease: Translational study in macaques

  2014cited by this paper
• Epigenetic drugs in cognitive disorders.

  2014cited by this paper
• Epigenetic regulation in neurodevelopment and neurodegenerative diseases.

  2014cited by this paper
• An expedient synthesis and screening for antiacetylcholinesterase activity of piperidine embedded novel pentacyclic cage compounds.

  2014cited by this paper
• Increased risk of dementia in people with previous exposure to general anesthesia: A nationwide population‐based case–control study

  2014cited by this paper
• Angiotensin Converting Enzyme Inhibitors and the Reduced Risk of Alzheimer’s Disease in the Absence of Apolipoprotein E4 Allele

  2014cited by this paper
• Targeting Estrogen Receptors for the Treatment of Alzheimer’s Disease

  2014cited by this paper
• Biochanin-A ameliorates behavioural and neurochemical derangements in cognitive-deficit mice for the betterment of Alzheimer’s disease

  2014cited by this paper
• Mitochondrial DNA deletions in Alzheimer's brains: A review

  2014cited by this paper
• Metalloporphyrins as Therapeutic Catalytic Oxidoreductants in Central Nervous System Disorders

  2014cited by this paper
• Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease

  2014cited by this paper
• APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease

  2014cited by this paper
• Alzheimer's disease: Review of hormone therapy trials and implications for treatment and prevention after menopause

  2014cited by this paper
• Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia

  2013cited by this paper
• Granulocyte colony stimulating factor (GCSF) improves memory and neurobehavior in an amyloid-β induced experimental model of Alzheimer's disease.

  2013cited by this paper
• Curcumin, an active constiuent of the ancient medicinal herb Curcuma longa L.: some uses and the establishment and biological basis of medical efficacy.

  2013cited by this paper
• In Vitro BACE1 Inhibitory Activity of Geraniin and Corilagin from Geranium thunbergii

  2013cited by this paper
• SAHA Enhances Synaptic Function and Plasticity In Vitro but Has Limited Brain Availability In Vivo and Does Not Impact Cognition

  2013cited by this paper
• Free and nanoencapsulated curcumin suppress β-amyloid-induced cognitive impairments in rats: involvement of BDNF and Akt/GSK-3β signaling pathway.

  2013cited by this paper
• Autophagy is involved in oligodendroglial precursor-mediated clearance of amyloid peptide

  2013cited by this paper
• Neuronal Autophagy: Self-eating or Self-cannibalism in Alzheimer’s Disease

  2013cited by this paper
• A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system

  2013cited by this paper
• Structural basis of kynurenine 3-monooxygenase inhibition

  2013cited by this paper
• The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease

  2013cited by this paper
• Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.

  2013cited by this paper
• Methylene blue induces macroautophagy through 5′ adenosine monophosphate-activated protein kinase pathway to protect neurons from serum deprivation

  2013cited by this paper
• A Cocoa Peptide Protects Caenorhabditis elegans from Oxidative Stress and β-Amyloid Peptide Toxicity

  2013cited by this paper
• Therapeutic strategies in Friedreich's ataxia.

  2013cited by this paper
• Necrostatin-1 inhibits the degeneration of neural cells induced by aluminum exposure

  2013cited by this paper
• 5,6-Dimethoxybenzofuran-3-one derivatives: a novel series of dual Acetylcholinesterase/Butyrylcholinesterase inhibitors bearing benzyl pyridinium moiety

  2013cited by this paper
• Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease

  2013cited by this paper
• A Novel Metabotropic Glutamate Receptor 5 Positive Allosteric Modulator Acts at a Unique Site and Confers Stimulus Bias to mGlu5 Signaling

  2013cited by this paper
• Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease

  2013cited by this paper
• The GERAS Study: A Prospective Observational Study of Costs and Resource Use in Community Dwellers with Alzheimer's Disease in Three European Countries – Study Design and Baseline Findings

  2013cited by this paper
• Identification of BACE1 inhibitors from Panax ginseng saponins - An Insilco approach

  2013cited by this paper
• Blood-brain barrier transport of amyloid beta peptides in efflux pump knock-out animals evaluated by in vivo optical imaging

  2013cited by this paper
• Arctigenin Effectively Ameliorates Memory Impairment in Alzheimer's Disease Model Mice Targeting Both β-Amyloid Production and Clearance

  2013cited by this paper
• Natural Compounds May Open New Routes to Treatment of Amyloid Diseases

  2013cited by this paper
• Combinatorial Treatment of Tart Cherry Extract and Essential Fatty Acids Reduces Cognitive Impairments and Inflammation in the mu-p75 Saporin-Induced Mouse Model of Alzheimer's Disease

  2013cited by this paper
• Resveratrol improves learning and memory in normally aged mice through microRNA-CREB pathway.

  2013cited by this paper
• AAD-2004 Attenuates Progressive Neuronal Loss in the Brain of Tg-betaCTF99/B6 Mouse Model of Alzheimer Disease

  2013cited by this paper
• Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer's disease treatment.

  2013cited by this paper
• Sulfiredoxin‐1 protects PC12 cells against oxidative stress induced by hydrogen peroxide

  2013cited by this paper
• Comparative evaluation of two dye probes in the rat everted gut sac model for unambiguous classification of P-gp substrate and inhibitor.

  2013cited by this paper
• Potential beneficial effects of marine peptide on human neuron health.

  2013cited by this paper
• The protective effect of geniposide on human neuroblastoma cells in the presence of formaldehyde

  2013cited by this paper
• The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice

  2013cited by this paper
• Long-Term Treatment of Thalidomide Ameliorates Amyloid-Like Pathology through Inhibition of β-Secretase in a Mouse Model of Alzheimer’s Disease

  2013cited by this paper
• Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model.

  2013cited by this paper
• The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France

  2013cited by this paper
• Diaminothiazoles Modify Tau Phosphorylation and Improve the Tauopathy in Mouse Models*♦

  2013cited by this paper
• Role of statins in Alzheimer's disease: a retrospective meta-analysis for commonly investigated clinical parameters in RCTs

  2013cited by this paper
• Effects of triptolide on degeneration of dendritic spines induced by Aβ1–40 injection in rat hippocampus

  2013cited by this paper
• Peptidyl-prolyl isomerase activity of FK506 binding protein 12 prevents tau peptide from aggregating.

  2013cited by this paper
• Protective Effects of Hydroxysafflor Yellow A on β-Amyloid-Induced Neurotoxicity in PC12 Cells

  2013cited by this paper
• Epigenetic signature and enhancer activity of the human APOE gene.

  2013cited by this paper
• Induction of Autophagy by a Novel Small Molecule Improves Aβ Pathology and Ameliorates Cognitive Deficits

  2013cited by this paper
• Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation*

  2013cited by this paper
• Salidroside attenuates beta amyloid-induced cognitive deficits via modulating oxidative stress and inflammatory mediators in rat hippocampus.

  2013cited by this paper
• Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.

  2013cited by this paper
• Development and mechanism of γ-secretase modulators for Alzheimer's disease.

  2013cited by this paper
• Ginsenoside Rg1 attenuates okadaic acid induced spatial memory impairment by the GSK3β/tau signaling pathway and the Aβ formation prevention in rats.

  2013cited by this paper
• Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation.

  2013cited by this paper
• The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease.

  2013cited by this paper
• Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors.

  2013cited by this paper
• The effect of PN-1, a Traditional Chinese Prescription, on the Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease

  2013cited by this paper
• The retinoic acid receptor agonist Am80 increases hippocampal ADAM10 in aged SAMP8 mice.

  2013cited by this paper
• LXR Agonists: New Potential Therapeutic Drug for Neurodegenerative Diseases

  2013cited by this paper
• Relationship between diet and plasma long-chain n-3 PUFAs in older people: impact of apolipoprotein E genotype

  2013cited by this paper
• Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease

  2013cited by this paper
• Early Intervention with an Estrogen Receptor β-Selective Phytoestrogenic Formulation Prolongs Survival, Improves Spatial Recognition Memory, and Slows Progression of Amyloid Pathology in a Female Mouse Model of Alzheimer's Disease

  2013cited by this paper
• Furan fatty acids efficiently rescue brain cells from cell death induced by oxidative stress.

  2013cited by this paper
• Biruloquinone, an acetylcholinesterase inhibitor produced by lichen-forming fungus Cladonia macilenta.

  2013cited by this paper
• The Molecular Chaperone GRP78/BiP as a Therapeutic Target for Neurodegenerative Disorders: A Mini Review.

  2013cited by this paper
• New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.

  2013cited by this paper
• In-vitro evaluation of selected Egyptian traditional herbal medicines for treatment of alzheimer disease

  2013cited by this paper
• Long‐term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease

  2013cited by this paper
• Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer’s disease mice

  2013cited by this paper
• Targeting the mTOR Signaling Network for Alzheimer’s Disease Therapy

  2013cited by this paper
• Simultaneous separation, identification and activity evaluation of three butyrylcholinesterase inhibitors from Plumula nelumbinis using on-line HPLC-UV coupled with ESI-IT-TOF-MS and BChE biochemical detection.

  2013cited by this paper
• Circulating miRNA Biomarkers for Alzheimer's Disease

  2013cited by this paper
• Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease

  2013cited by this paper
• Population Pharmacokinetic Study of Memantine: Effects of Clinical and Genetic Factors

  2013cited by this paper
• Sciadopitysin: active component from Taxus chinensis for anti-Alzheimer's disease

  2013cited by this paper

• Tailoring treatments: pharmacogenomics in the management of neurodegenerative diseases.

  2026cites this paper
• Targeting Alzheimer’s Disease via Phytochemicals from Artemisia campestris L.: GC/MS Analysis with an Integrated Computational Approach

  2025cites this paper
• The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress

  2025cites this paper
• Porphyrin Schiff bases as potential Alzheimer's disease drug candidates: Synthesis, in silico and DFT studies

  2024cites this paper
• Pharmacogenetics of anxiety and depression in Alzheimer's disease.

  2023cites this paper
• Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases

  2023cites this paper
• Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.

  2022cites this paper
• What have we learnt from past failures in Alzheimer’s disease drug discovery?

  2022cites this paper
• Personalized Management and Treatment of Alzheimer’s Disease

  2022influential citation
• A Review of the Recent Advances in Alzheimer’s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics

  2022cites this paper
• Metabolic disorder in Alzheimer’s disease

  2021cites this paper
• Reversible Chemosensor for Bioimaging and Biosensing of Zn(II) and hpH in Cells, Larval Zebrafish, and Plants with Dual-Channel Fluorescence Signals.

  2021cites this paper
• Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer’s Disease

  2021cites this paper
• Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics

  2021cites this paper
• ER stress associated TXNIP-NLRP3 inflammasome activation in hippocampus of human Alzheimer's disease.

  2021cites this paper
• What is the gold standard model for Alzheimer’s disease drug discovery and development?

  2021cites this paper
• Proteome Analysis and In Vitro Antiviral, Anticancer and Antioxidant Capacities of the Aqueous Extracts of Lentinula edodes and Pleurotus ostreatus Edible Mushrooms

  2021cites this paper
• Investigation of B2-AR, TLR2, PICALM, and BDNF Gene Variants in Iranian Alzheimer’s Patients and Their Response to Rivastigmine

  2021cites this paper
• Zinc Binding to NAP-Type Neuroprotective Peptides: Nuclear Magnetic Resonance Studies and Molecular Modeling

  2021cites this paper
• Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions

  2021cites this paper
• Pharmacogenetic and Association Studies on the Influence of HLA Alleles and Rivastigmine on the Iranian Patients with Late-Onset Alzheimer’s Disease

  2021cites this paper
• The PharmacoEpiGenetic Connection

  2020cites this paper
• Pharmacogenomics of drugs used to treat brain disorders

  2020cites this paper
• Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia

  2020cites this paper
• Pharmacogenomics of Alzheimer's and Parkinson's diseases.

  2020influential citation
• Editorial-MS CPPM 17-2

  2020cites this paper
• Lipid nanoparticles as carriers for the treatment of neurodegeneration associated with Alzheimer's disease and glaucoma: present and future challenges.

  2020cites this paper
• Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease

  2020cites this paper
• Possible Epigenetic Role of Vitexin in Regulating Neuroinflammation in Alzheimer's Disease

  2020cites this paper
• Circumdatin D Exerts Neuroprotective Effects by Attenuating LPS-Induced Pro-Inflammatory Responses and Downregulating Acetylcholinesterase Activity In Vitro and In Vivo

  2020cites this paper
• Formulation and evaluation of rutin-loaded solid lipid nanoparticles for the treatment of brain tumor

  2020cites this paper
• Epigenetic treatment of neurodegenerative disorders

  2020cites this paper
• Epigenetics and Pharmacoepigenetics of Neurodevelopmental and Neuropsychiatric Disorders

  2019cites this paper
• Sirtuins in Alzheimer’s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics

  2019influential citation
• The role of pharmacogenomics in adverse drug reactions

  2019influential citation
• Epigenetic Mechanisms in the Regulation of Drug Metabolism and Transport

  2019cites this paper
• Pharmacoepigenetic Processors: Epigenetic Drugs, Drug Resistance, Toxicoepigenetics, and Nutriepigenetics

  2019cites this paper
• The Epigenetic Machinery in the Life Cycle and Pharmacoepigenetics

  2019cites this paper
• ACAT1 as a therapeutic target and its genetic relationship with Alzheimer's disease.

  2019cites this paper
• Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinsonʼs Disease

  2019cites this paper
• Epigenetics and Pharmacoepigenetics of Age-Related Neurodegenerative Disorders

  2019cites this paper
• Population-level pharmacogenomics for precision drug development in dementia

  2018influential citation
• Ebselen inhibits the activity of acetylcholinesterase globular isoform G4 in vitro and attenuates scopolamine‐induced amnesia in mice

  2018cites this paper
• Pharmacogenetics of Vascular Risk Factors in Alzheimer’s Disease

  2018cites this paper
• Proteomics and lipidomics in the human brain.

  2018cites this paper
• Basic and Clinical Studies With Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders

  2018cites this paper
• Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years?

  2018cites this paper
• Exosomes: a novel therapeutic target for Alzheimer’s disease?

  2018cites this paper
• Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases

  2018influential citation
• Age-related hearing loss and neurocognitive function: Normal and pathological processes in cognitive ageing

  2018cites this paper
• Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer's disease and related risk factors

  2018cites this paper
• Epigenomics and Proteomics of Brain Disorders

  2017cites this paper
• Cellular acidification as a new approach to cancer treatment and to the understanding and therapeutics of neurodegenerative diseases.

  2017cites this paper
• Parkinson’s Disease: From Pathogenesis to Pharmacogenomics

  2017cites this paper
• Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration

  2017cites this paper
• Neuroepigenetics: Prospects and Illusions

  2017cites this paper
• Some News on Old Concepts and the Epigenetics of Alzheimerâs Disease

  2017cites this paper
• Risk Factors for Alzheimer’s Disease

  2017cites this paper
• Pharmacogenomics of Neurodegenerative Diseases: Roles in Personalized Medicines

  2017cites this paper
• Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies.

  2017cites this paper
• Chapter 32 – Pharmacoepigenomics

  2016cites this paper
• Epigenetics of Brain Disorders: The Paradigm of Alzheimers Disease

  2016cites this paper
• Validating Immunotherapy in Alzheimer's Disease: The EB101 Vaccine.

  2016cites this paper
• Gene Interactions in the Pharmacogenomics of Alzheimer’s Disease

  2016influential citation
• Proteomic Biomarkers in Alzheimer's disease

  2016cites this paper
• Nutriepigenomics: Mending Ideas in Nutrition, Health and Disease

  2016influential citation
• Can cloud-based tools accelerate Alzheimer’s disease drug discovery?

  2016influential citation
• Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection.

  2016cites this paper
• Pharmacogenetic considerations in the treatment of Alzheimer's disease.

  2016cites this paper
• Novel Biotechnological Products from Natural Sources: Nutri/ Pharmacogenomic Component

  2016cites this paper
• Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments.

  2016cites this paper
• Novel Therapeutic Strategies for Dementia.

  2016cites this paper
• Impact of Genomic Medicine on the Future of Neuropsychopharmacology

  2016influential citation
• Biochemical Changes and Cardiovascular Function in Parkinson’s Disease: Precautionary Notes

  2016cites this paper
• Pharmacogenomics of Antidepressant Drugs

  2016cites this paper
• Trial-and-Error Versus Personalized Treatment in Depression: The Power of Pharmacogenomics

  2016cites this paper
• Proteoepigenomic Biomarkers of Brain Disorders

  2016cites this paper
• Epigenetics a Promising Therapy for Future Disease Cure

  2016cites this paper
• The Complexity of Alzheimers Disease Pharmacogenomics and Metabolomics in Drug Development

  2016cites this paper
• The Complexity of Alzheimer ’ Metabolomics in Drug Development s Disease Pharmacogenomics and

  2016cites this paper
• Parkinson's Disease: Old Concepts and New Challenges

  2016cites this paper
• Pharmacogenomics and its Implementations

  2015cites this paper
• Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response

  2015cites this paper
• Pharmacogenetic Study on the Impact of Rivastigmine Concerning Genetic Variants of A2M and IL-6 Genes on Iranian Alzheimer’s Patients

  2015cites this paper
• Opportunities in pharmacogenomics for the treatment of Alzheimer's disease

  2015cites this paper
• Pharmacoepigenomics and the Metabolomics of Drug Efficacy and Safety

  2015cites this paper
• Pharmacogenomics in Drug Discovery and Development

  2014cites this paper
• The Pathogenic Component of the APOE-TOMM40 Region in Alzheimer’s disease: Its Implications in Metabolomics and Pharmacogenomics

  2014cites this paper
• Epigenomic Networking in Drug Development: From Pathogenic Mechanisms to Pharmacogenomics

  2014cites this paper
• Epigenetic drug discovery for Alzheimer’s disease

  2014influential citation
• APOE-TOMM40 in the Pharmacogenomics of Dementia

  2013cites this paper
• HSOA Journal of Psychiatry, Depression & Anxiety

  year unknowncites this paper